EYLEA [AMD-QOL(Age-Related Macular Degeneration-Quality of Life)] Post-marketing Surveillance in Japan
Special Drug Use Investigation of EYLEA for Quality of Life
Sponsor: Bayer
A observational or N/A phase clinical study on Macular Degeneration, this trial is completed. The trial is conducted by Bayer and has accumulated 11 data snapshots since 2012. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2021 — Jul 2024 [monthly]
Completed
-
Jul 2018 — Jan 2021 [monthly]
Completed
-
Jun 2018 — Jul 2018 [monthly]
Completed
▶ Show 6 earlier versions
-
Apr 2018 — Jun 2018 [monthly]
Completed
Phase: NA → None
-
Mar 2018 — Apr 2018 [monthly]
Completed NA
Status: Active Not Recruiting → Completed
-
Dec 2017 — Mar 2018 [monthly]
Active Not Recruiting NA
-
Jul 2017 — Dec 2017 [monthly]
Active Not Recruiting NA
-
Feb 2017 — Jul 2017 [monthly]
Active Not Recruiting NA
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting NA
First recorded
Dec 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bayer
- Regeneron Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .